WHITE PLAINS, N.Y., April 23, 2024, Clarapath, a medical robotics company
transforming the way pathology laboratories process tissue, announced it has entered
into a strategic collaboration with Mayo Clinic to propel a new era of laboratory
automation.

​

For decades, laboratories have relied on labor intensive, manual procedures to process
tissue specimens for purposes of diagnosing cancer and other diseases. Faced with
labor shortages, quality control challenges, and the rapidly increasing volume of
samples, laboratories need to innovate and improve the reliability and efficiency of
creating glass slides for pathological review. Clarapath’s SectionStar™ is an automated
tissue sectioning, transfer and quality control system that combines robotics,
computational AI, and integrated histopathology workflows, resulting in standardized
slide outputs and quantitative quality metrics. This can significantly accelerate sample
processing and reduce human involvement and errors.

​

The strategic collaboration combines Clarapath’s innovative tissue solution and domain
experts with the clinical insights and expertise of Mayo Clinic. This will enable
laboratories across the globe to digitally transform the quality, safety, cost, and
throughput of their histology process. The automation supports more informed and
faster decisions that help improve the delivery and quality of patient care and allow
existing laboratory personnel to successfully handle rising case volumes. Additionally,
the companies will collaborate to develop new solutions to further improve the
histopathology laboratory.

​

“We are thrilled to collaborate with Mayo Clinic to advance the modernization of
anatomic pathology,” said Eric Feinstein, CEO of Clarapath. “Laboratories, like
manufacturing plants, need constant innovation and modernization. With SectionStar,
leaders can now reimagine the histology process to keep up with increasing caseloads
and shrinking workforces. This will help patients get quicker test results and more
immediate access to care."

​

As part of the collaboration, Joaquín García, M.D., chair of the division of Anatomic
Pathology within the Department of Laboratory Medicine and Pathology and chair of
Mayo Clinic's Digital Pathology Program, is joining the Clarapath Board of Directors.
Mayo Clinic joins other leading organizations as Clarapath stakeholders.

 

“Mayo Clinic is at the leading edge of technological advancement in anatomic
pathology. Incorporating digital pathology and artificial intelligence into our current
practice has highlighted the need for standardizing pre-analytic processes,” said Dr.
García. By working with Clarapath, we are building the foundation for a 'lab of the
future' that incorporates end-to-end automation, robotics, and AI to the patient tissue
lifecycle.”

Mayo Clinic has a financial interest in the technology referenced in this press release.
Mayo Clinic will use any revenue it receives to support its not-for-profit mission in
patient care, education and research.

​

About Clarapath
Clarapath is a medical robotics company aimed at catalyzing change in the way pathology
laboratories work. Clarapath's SectionStar is the first (pending US launch) all-in-one tissue
sectioning and transfer system that dramatically increases capacity, reliability, and consistency
while minimizing the need for highly skilled labor. The company is headquartered and runs its
medical device development in Hawthorne, NY. It has a CLIA-certified laboratory that serves
clinical and non-clinical organizations. For more information, visit https://www.clarapath.com/

Media contact:
Claire Rowberry, 617 785 5571, claire@clearcommsc.com